Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EPS (Basic): 2015-2025

Historic EPS (Basic) for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $0.94.

  • Seres Therapeutics' EPS (Basic) fell 91.92% to $0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was $16.30, marking a year-over-year increase of 965.36%. This contributed to the annual value of -$0.81 for FY2024, which is 45.64% up from last year.
  • Latest data reveals that Seres Therapeutics reported EPS (Basic) of $0.94 as of Q3 2025, which was up 141.41% from -$2.27 recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' EPS (Basic) peaked at $13.87 during Q4 2024, and registered a low of -$5.49 during Q1 2024.
  • Its 3-year average for EPS (Basic) is $1.57, with a median of -$0.27 in 2023.
  • Data for Seres Therapeutics' EPS (Basic) shows a peak YoY increase of 5,237.04% (in 2024) and a maximum YoY decrease of 1,305.56% (in 2024) over the last 5 years.
  • Seres Therapeutics' EPS (Basic) (Quarterly) stood at -$0.55 in 2021, then rose by 1.82% to -$0.54 in 2022, then soared by 50.00% to -$0.27 in 2023, then skyrocketed by 5,237.04% to $13.87 in 2024, then crashed by 91.92% to $0.94 in 2025.
  • Its last three reported values are $0.94 in Q3 2025, -$2.27 for Q2 2025, and $3.76 during Q1 2025.